Abstract
The clinical observations that LUTS in men with BPH is relieved by α-blockers, 5-α-reductase (5AR) inhibitors, and phosphodiesterase (PDE) inhibitors imply that α-adrenoceptors and the downstream products of 5AR and PDE are involved in the pathophysiology of these symptoms. The specific targets mediating the effectiveness of these 3 classes of drugs remain poorly understood. Over the past 30 years, we have learned how to effectively treat LUTS secondary to BPH without unraveling the underlying pathophysiology of LUTS/BPH. 1 Shapiro E. Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am. 1995; 22: 285 PubMed Google Scholar Dose-ranging Study of the Luteinizing Hormone-releasing Hormone Receptor Antagonist Cetrorelix Pamoate in the Treatment of Patients With Symptomatic Benign Prostatic HyperplasiaUrologyVol. 76Issue 4PreviewTo compare the efficacy of 4 dosage regimens of cetrorelix pamoate, a sustained release formulation that allows for more convenient dosing, in patients with symptomatic benign prostatic hyperplasia (BPH). Repeated dosing with cetrorelix acetate was shown to be active in the treatment of BPH symptoms. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
